Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441479 · ClinicalTrials.gov registry record
Strep A Fluorescent Immunoassay and Analyzer Field Study
A clinical trial of Strep Throat, sponsored by Quidel Corporation.
- Completed
- Registry status
- 1,282
- Enrollment target
- 7
- Study locations
NCT01441479: Completed study of Strep Throat, sponsored by Quidel Corporation.
NCT01441479 is a study of Strep Throat that has completed, run by Quidel Corporation. The registered enrollment target is 1,282 participants. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01441479, a study of Strep Throat, has completed, sponsored by Quidel Corporation.
- COMPLETED
- Registry status
- 1,282 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to demonstrate the ability of the Strep A Fluorescent Immunoassay Analyzer to accurately detect a throat swab specimen for the presence or absence of Strep A when compared to culture.
Primary Outcome
The purpose of this study was to identify via immunofluorescence technology, Group A Streptococcus, which was successfully done.
Conditions Studied
Interventions
- DEVICE In Vitro Diagnostic Device aid in diagnosing
Study Locations (7)
California
- La Costa Pediatrics - Carlsbad
- La Jolla Pediatrics - San Diego
Arizona
- Best Medical Group - Phoenix
Florida
- Teena Hughes - Tampa
New Jersey
- FastER Urgent Care - Morris Plains
New York
- Twelve Corners Pediatrics - Rochester
Virginia
- Advanced Pediatrics - Vienna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,282 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-12 |
What the finished NCT01441479 record still lists
NCT01441479 is an observational study that tracks outcomes without assigning an intervention. Its 1,282 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Strep Throat appearing as the primary indexed condition, and to 1 intervention - of which In Vitro Diagnostic Device aid in diagnosing is the first listed.
NCT01441479 lists 7 locations in 6 states (California, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT01441479 about?
NCT01441479 is a clinical study titled "Strep A Fluorescent Immunoassay and Analyzer Field Study". The purpose of this study is to demonstrate the ability of the Strep A Fluorescent Immunoassay Analyzer to accurately detect a throat swab specimen for the presence or absence of Strep A when compared to culture.
What is the current status of trial NCT01441479?
This trial is currently completed. The enrollment target is 1,282 participants. The study started on 2011-06. Estimated completion is 2012-12.
What conditions does trial NCT01441479 study?
This clinical trial studies the following conditions: Strep Throat.
What interventions are being tested in trial NCT01441479?
The interventions under investigation include: In Vitro Diagnostic Device aid in diagnosing (DEVICE).
Who is sponsoring clinical trial NCT01441479?
This trial is sponsored by Quidel Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01441479 being conducted?
This trial has 7 study locations across Arizona, California, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Strep Throat
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia